Intervention

WB-MRI

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions5

Lead sponsors shown5

Clinical trials

5 shown

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)NCT05208229 · 2021-02-01

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to TherapyNCT03619655 · 2019-11-15

Whole Body Magnetic Resonance Imaging StudyNCT04117594 · 2019-10-09

Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the BoneNCT06321666 · 2019-09-12

Diagnostic Imaging of Bone Metastases in Prostate Cancer PatientsNCT03134261 · 2014-04-01

Common conditions

Advanced Prostate Cancer1 Metastatic Breast Cancer1 Metastatic Castration Resistant Prostate Cancer (mCRPC)1 Prostate Cancer1 Prostate Cancer Metastatic to Bone1

Leading sponsors

European Institute of Oncology1 Herlev Hospital1 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1 Royal Marsden NHS Foundation Trust1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1

Trial status mix

UNKNOWN3

TERMINATED2

Phase mix

NA2

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.